This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry http://www.reportlinker.com/p01120885/Financial-Assessment-of-the-Global-Pharmaceutical-and-Biotechnology-Industry .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
Financial Management is the Key Strategy for Sustainability
This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.
The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:•The global economic slowdown•Regulatory compliance•Reducing profitability•Increasing R&D costs•Pricing pressures•Counterfeit business
Financial Analysis of the Pharmaceutical and Biotechnology Industry1. Margin Analysis•The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures, and decreasing healthcare spending.•In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins because of the heavy investment in R&D and SG&A (selling and general expenses).
2. Profitability Analysis•Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.•The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue.
3. Turnover Analysis•In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge investments made in assets and in the development of the product.
4. Cash Reserve Analysis•In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their assets.•In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage of their assets.
5. R&D to Sales Ratio•Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries, the R&D expenses were not considerably reduced.
Who Will Benefit?•Pharmaceutical & biotechnology companies•Private equity•Venture capital investors•Fund managers•Retail investors•Sovereign wealth funds•Hedge funds•Insurance funds and other members of the investing community
Table Of Contents1. Executive Summary2. Definition of Key Terms3. Research Objective and Scope4. Research Methodology5. Key Issues/Challenges Faced by Industry Participants6. Pharmaceutical Industry7. Top Performers in the Pharmaceutical Industry8. Biotechnology Industry9. Top Performers in the Biotechnology Industry10. The Frost & Sullivan StoryTo order this report: Pharmaceutical Industry: Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
firstname.lastname@example.orgUS:(339) 368 6001Intl:+1 339 368 6001